Lecap Asset Management Ltd. Sells 1,317 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Lecap Asset Management Ltd. decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 29.9% in the 1st quarter, HoldingsChannel reports. The firm owned 3,091 shares of the medical research company’s stock after selling 1,317 shares during the quarter. Lecap Asset Management Ltd.’s holdings in Thermo Fisher Scientific were worth $1,538,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of TMO. Global Assets Advisory LLC bought a new stake in shares of Thermo Fisher Scientific during the first quarter worth $251,000. Mill Capital Management LLC raised its position in shares of Thermo Fisher Scientific by 0.3% during the first quarter. Mill Capital Management LLC now owns 79,029 shares of the medical research company’s stock worth $39,325,000 after acquiring an additional 251 shares during the last quarter. Strategic Investment Advisors MI raised its position in shares of Thermo Fisher Scientific by 17.3% during the first quarter. Strategic Investment Advisors MI now owns 1,005 shares of the medical research company’s stock worth $500,000 after acquiring an additional 148 shares during the last quarter. International Assets Investment Management LLC raised its position in shares of Thermo Fisher Scientific by 18.1% during the first quarter. International Assets Investment Management LLC now owns 2,175 shares of the medical research company’s stock worth $1,082,000 after acquiring an additional 334 shares during the last quarter. Finally, Invesco LLC raised its position in shares of Thermo Fisher Scientific by 2.6% during the first quarter. Invesco LLC now owns 11,156 shares of the medical research company’s stock worth $5,551,000 after acquiring an additional 286 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $410.45 on Thursday. The firm has a market cap of $154.94 billion, a price-to-earnings ratio of 24.07, a price-to-earnings-growth ratio of 2.13 and a beta of 0.78. The stock’s 50-day moving average is $410.39 and its 200-day moving average is $485.33. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company’s quarterly revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the company posted $5.11 earnings per share. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.42%. Thermo Fisher Scientific’s payout ratio is presently 10.09%.

Analyst Ratings Changes

TMO has been the subject of a number of recent research reports. Argus dropped their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating for the company in a research report on Tuesday, April 29th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, May 21st. Evercore ISI decreased their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Wednesday, April 23rd. Finally, Royal Bank Of Canada decreased their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $604.05.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.33% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.